Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Doji - Bullish? | Reversal | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Doji - Bullish? | Reversal | 0.06% | |
Outside Day | Range Expansion | -0.68% | |
Wide Bands | Range Expansion | -0.68% | |
Gapped Up | Strength | -0.68% | |
Wide Bands | Range Expansion | -3.25% | |
Gapped Up | Strength | -3.25% | |
NR7 | Range Contraction | -0.74% | |
NR7-2 | Range Contraction | -0.74% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 11 hours ago |
Outside Day | about 11 hours ago |
Rose Above 10 DMA | about 11 hours ago |
10 DMA Resistance | about 12 hours ago |
Up 1% | about 12 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Medication Disorders Virotherapy Epilepsy Pharmaceutical Sciences Prescription Drugs Stage Specialty Pharmaceutical Myasthenia Pharmaceutical Partners Treatment Of Epilepsy Urological Diseases Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Tourette Syndrome Treatment Of Tourette Syndrome
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Medication Disorders Virotherapy Epilepsy Pharmaceutical Sciences Prescription Drugs Stage Specialty Pharmaceutical Myasthenia Pharmaceutical Partners Treatment Of Epilepsy Urological Diseases Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Tourette Syndrome Treatment Of Tourette Syndrome
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 18.2 |
52 Week Low | 11.09 |
Average Volume | 1,555,012 |
200-Day Moving Average | 13.77 |
50-Day Moving Average | 14.78 |
20-Day Moving Average | 15.53 |
10-Day Moving Average | 16.23 |
Average True Range | 0.65 |
RSI (14) | 57.08 |
ADX | 33.04 |
+DI | 29.40 |
-DI | 16.02 |
Chandelier Exit (Long, 3 ATRs) | 15.55 |
Chandelier Exit (Short, 3 ATRs) | 15.44 |
Upper Bollinger Bands | 17.74 |
Lower Bollinger Band | 13.31 |
Percent B (%b) | 0.62 |
BandWidth | 28.55 |
MACD Line | 0.51 |
MACD Signal Line | 0.50 |
MACD Histogram | 0.0114 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 17.03 | ||||
Resistance 3 (R3) | 17.03 | 16.71 | 16.87 | ||
Resistance 2 (R2) | 16.71 | 16.46 | 16.71 | 16.82 | |
Resistance 1 (R1) | 16.39 | 16.31 | 16.55 | 16.40 | 16.77 |
Pivot Point | 16.07 | 16.07 | 16.15 | 16.07 | 16.07 |
Support 1 (S1) | 15.76 | 15.83 | 15.92 | 15.76 | 15.39 |
Support 2 (S2) | 15.44 | 15.68 | 15.44 | 15.34 | |
Support 3 (S3) | 15.12 | 15.44 | 15.29 | ||
Support 4 (S4) | 15.13 |